Leishmanicidal activity of amphotericin B encapsulated in PLGA–DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice

Carvalho, Ricardo Fontoura de; Ribeiro, Ieler Ferreira; Miranda-Vilela, Ana Luisa; Filho, José de Souza; Martins, Olímpia Paschoal; Silva, Débora de Oliveira Cintra e; Tedesco, Antônio Cláudio; Lacava, Z.G.M.; Báo, Sônia Nair; Sampaio, Raimunda Nonata Ribeiro

doi:10.1016/j.exppara.2013.07.008

Cited by 67 publications

(48 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors showed that this formulation was effective in penetrating the blood-brain barrier of the animals, and AmpB was found to be concentrated in the brain. Carvalho et al (42) developed a system containing free desoxycholate AmpB encapsulated in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA), yielding PLGA-DMSA nanoparticles. These products were evaluated in the treatment of experimental cutaneous leishmaniasis in C57BL/6 mice to determine whether the nano-drug delivery system would favor a reduction in the dose frequency required to achieve the same therapeutic level as free AmpB, thereby extending the dosing interval.…”

Section: Amphotericin B and Its Delivery Systems For The Treatment Ofmentioning

confidence: 99%

New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment

Chávez-Fumagalli

Ribeiro

Castilho

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit rati

show abstract

Section: Amphotericin B and Its Delivery Systems For The Treatment Ofmentioning

confidence: 99%

New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment

Chávez-Fumagalli

Ribeiro

Castilho

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…anti-leishmanial therapy [14][15][16][17]. Although glucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liver enzymes and electrocardiogram changes [17].…”

Section: Methodsmentioning

confidence: 99%

“…The current management of leishmaniasis is drug treatment of patients, to alleviate disease and vector control to reduce its transmission [12][13][14]. Pentavalent antimonials (namely, sodium stibogluconate (SSG) and meglumine antimoniate) are the mainstay of…”

Section: Introductionmentioning

confidence: 99%

Application of Nano Drugs in Treatment of Leishmaniasis

Shahcheraghi¹

2016

Glob J Infect Dis Clin Res

View full text Add to dashboard Cite

Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most common form of leishmaniasis is cutaneous leishmaniasis (CL) with 1.5 million new cases per year. Correct diagnosis and characterization of the particular parasite is important for evaluating prognosis and prescribing appropriate treatment. The current management of leishmaniasis is drug treatment of patients, to alleviate disease and vector control to reduce its transmission. Also, current treatments for visceral leishmaniasis are unsatisfactory because of their toxicity, resistance and high cost. The purpose of the present study was to review the application of nano drugs in treatment of leishmaniasis. Materials and Methods:it was used as source of research the following databases: MEDLINE, Cochrane Library, Scielo, PubMed and the database of CAPES.Results: It has been proved nanosilver particles with highly small sizes, have a good penetration into the cutaneous lesions and a good efficacy on leishmaniasis.anti-leishmanial therapy [14][15][16][17]. Although glucantime is commonly used for the treatment of leishmaniasis, it has some side effects including increased liver enzymes and electrocardiogram changes [17]. In addition, the drug is expensive, the injection is painful, and research shows that resistance of parasite to glucantime is growing in different parts of the world [17][18][19][20]. The use of nanotechnology is ever-expanding in today's technologically advanced world. This form of technology has many advantages over existing ones in many fields and medicine is one of them [20]. There are numerous devices and mechanisms developed with the aid of nanotechnology that can help cure diseases/disorders in a much better and more efficient manner [21]. The usefulness of nanotechnology can especially be seen in the treatment of infectious diseases [21,22]. This review has investigated the treatment of leishmaniasis by nano drugs. Nano drugs against leishmaniasisNanotechnology must be applied for curing infectious disease like leishmaniasis [22]. Many drugs have been made and are still being discovered, but the protozoan re-emerges showing drug resistance to the effective medications [23]. Nanotechnology has just managed to show its promise in developing a liposomal formulation called amphotericin B for leishmaniasis but has serious side effects and is not cost effective in developing countries [23][24][25]. Initial, nanodelivery systems for delivering chemotherapeutics were nanodisks impregnanted with amphotericin B, polymericnanoparticle loaded with pentamidine, primaquine, and niosomes, which still need validation at the clinical level [25][26][27][28]. There is an urgent need to take up assignments to use effective nanotechnology devices in combating this infectious disease [25][26][27][28].Different mechanisms were proposed for antimicrobial property of nanoparticles [28]. One mechanism is binding of nanoparticle to sulfur/ phosphorus-containing biomolecules such as proteins and DNA, which leads to...

show abstract

“…and Plasmodium sp. [40,41]. Nano-particles have also shown improvement in the bioavailability and drug selectivity, even in very complicated treatments like cerebral malaria by Plasmodium falciparum infection [41].…”

Section: Neurocysticercosis (Ncc)mentioning

confidence: 99%